TD Cowen Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $185
HSBC Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $184
Guggenheim Adjusts Price Target on Johnson & Johnson to $164 From $166, Keeps Neutral Rating
Barclays Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $165
Barclays Keeps Their Hold Rating on Johnson & Johnson (JNJ)
Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $169
Johnson & Johnson Analyst Ratings
Johnson & Johnson Is Maintained at Equal-Weight by Barclays
Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Announces Target Price $169
Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating
UBS Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $180
Johnson & Johnson Price Target Raised to $164.00/Share From $162.00 by Raymond James
Johnson & Johnson Is Maintained at Outperform by Raymond James
Johnson & Johnson Analyst Ratings
RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $181 Price Target
A Quick Look at Today's Ratings for Johnson & Johnson(JNJ.US), With a Forecast Between $159 to $185
Bernstein Adjusts Price Target on Johnson & Johnson to $159 From $158, Keeps Market Perform Rating
Johnson & Johnson Stock: Fairly Valued With Neutral Outlook Amid Uncertain Growth Prospects
Johnson & Johnson (JNJ) Receives a Hold From Barclays
Research Alert: Jnj Reported Better-than-expected Q1 Performance, Driven By Innovative Medicine